Early detection of gastric cancer and premalignant gastric pathology remains a key unmet need in gastroenterology, particularly in low-incidence settings where universal endoscopic screening is neither practical nor cost-effective. Point-of-care blood tests Serological biomarkers provide a non-invasive method of risk stratification by assessing serological biomarkers such as pepsinogen I/II ratios, gastrin-17, and Helicobacter pylori serology, enabling identification of atrophic gastritis and other high-risk states.

In this presentation, we will explore the clinical utility of these serological biomarkers as a potential triage tool to guide endoscopic decision-making. Its use may allow endoscopists to prioritise patients at higher risk of significant pathology, improving early detection of gastric cancer and its precursors, while reducing unnecessary endoscopies in low-risk individuals.

We will present preliminary data from the CyGIM study, highlighting the performance of this approach in a real-world cohort and its potential role within current diagnostic pathways. The implications for service efficiency, patient selection, and personalised risk-based screening strategies will be discussed.

This approach may represent an important step toward more targeted, evidence-based prevention of gastric cancer.

Speaker: 

Andreas Hadjinicolaou – Gastroenterology Consultant